The Semaglutide Cliff vs. a 10x Multiple: Is Novo Nordisk (NVO) a Value Trap or a Bargain?
Morgan Stanley has cut Novo Nordisk A/S (NYSE:NVO) to Underweight on September 11, 2026. Semaglutide, the underlying molecule…
Merck’s Stock is Suddenly Soaring, but Is the Struggling Healthcare Giant a Buy?
Merck shares began peeling back in early 2024, mostly on concerns about looming patent expirations for its breadwinning…